Omicron may not attack the lungs as effectively as earlier versions of the coronavirus. This is according to a study by the Institute of Therapeutic Immunology and Infectious Diseases in Cambridge, quoted by DPA.
The conclusion is that mutations in the virus’s thorn protein, which allow it to fight antibodies, can also reduce its reproduction in the lungs, which would lead to severe disease.
These observations emphasize that Omicron has acquired properties to avoid immunitywhile compromising replication and pathogenicity properties, the study summary states.
Omicron-infected people double in a day and a half to 3 days in areas with local distribution
To date, there is no evidence that the vaccine is effective for Omicron
–
The study’s lead author, Ravi Gupta, a professor of clinical microbiology at Cambridge, explained that despite seemingly optimistic findings, challenges remain.
He explained that the study concluded that effective lung cell infection could be commensurate with the severity of the lung disease. Syncytia, ie fused cells, are often seen in lung tissue taken after severe illness. The delta version was very good in both, unlike Omicron, Gupta said, adding that more work was needed.
It is supposed to Omicron has become more adaptive to immunity, but its disease-related properties may be weakened somewhat. However, the rapid deployment of the new version of COVID-19 poses a major public health challenge.
–
WHO concerned over opinion on “light Omicron”
I have never been more worried about a pandemic than I am now, says the WHO Special Envoy for COVID-19.
–
– .
